Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 17, 2016

Primary Completion Date

June 27, 2016

Study Completion Date

June 27, 2016

Conditions

NeoplasmsFebrile Neutropenia

Interventions

DRUG

CAZ-AVI

Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)

DRUG

Vancomycin

15 mg/kg

DRUG

Linezolid

600 mg

DRUG

Cefepime

2 g

DRUG

Meropenem

1 g

DRUG

Piperacillin/tazobactam

4.5 g

Trial Locations (1)

MD Anderson Cancer Center, Houston